Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Open in Screener

SLRN

Acelyrin Inc

May 03 • 04:00PM ET

4.35

Dollar change +0.10
Percentage change 2.35	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB VBK IWM VXF IBB VTWO IWN IWO SCHA

Index	RUT	P/E	-	EPS (ttm)	-3.92	Insider Own	37.98%	Shs Outstand	97.87M	Perf Week	2.59%
Market Cap	430.26M	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-0.10%	Shs Float	61.35M	Perf Month	-31.92%
Income	-381.64M	PEG	-	EPS next Q	-0.96	Inst Own	72.80%	Short Float	12.79%	Perf Quarter	-45.90%
Sales	0.00M	P/S	-	EPS this Y	24.27%	Inst Trans	-	Short Ratio	6.30	Perf Half Y	-52.35%
Book/sh	6.71	P/B	0.65	EPS next Y	-15.86%	ROA	-	Short Interest	7.85M	Perf Year	-
Cash/sh	7.29	P/C	0.60	EPS next 5Y	-	ROE	-	52W Range	4.14 - 29.88	Perf YTD	-41.69%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-58.04%	52W High	-85.44%	Beta	2.45
Dividend TTM	-	Quick Ratio	8.65	Sales past 5Y	0.00%	Gross Margin	-	52W Low	5.07%	ATR (14)	0.34
Dividend Ex-Date	-	Current Ratio	8.65	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	26.41	Volatility	4.44% 6.03%
Employees	130	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.40	Target Price	31.00
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	-526.06%	Payout	-	Rel Volume	0.76	Prev Close	4.25
Sales Surprise	-	EPS Surprise	551.50%	Sales Q/Q	-	Earnings	May 13 AMC	Avg Volume	1.25M	Price	4.35
SMA20	-12.88%	SMA50	-34.06%	SMA200	-61.16%	Trades		Volume	946,404	Change	2.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-13-23	Initiated	Wells Fargo	Equal Weight	$11
Dec-08-23	Initiated	Citigroup	Neutral	$8
Sep-13-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$19
Sep-05-23	Initiated	H.C. Wainwright	Buy	$44
May-30-23	Initiated	TD Cowen	Outperform
May-30-23	Initiated	Piper Sandler	Overweight	$68
May-30-23	Initiated	Morgan Stanley	Overweight
May-30-23	Initiated	Jefferies	Buy	$31

Apr-29-24 04:05PM	ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024 (GlobeNewswire)
Mar-28-24 10:53PM	SLRN Stock Earnings: Acelyrin Beats EPS for Q4 2023 (InvestorPlace)
04:05PM	ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights (GlobeNewswire)
Mar-27-24 04:01PM	Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million (GlobeNewswire)
Mar-21-24 11:12AM	ACELYRIN (SLRN) Up on Data From Thyroid Eye Disease Study (Zacks) -6.49%
07:00AM	Loading…
Mar-20-24 07:00AM	ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye Disease (GlobeNewswire)
12:39AM	Acelyrin adds proof-of-concept TED data to recent readout pile, cementing challenge to Amgen (FierceBiotech.com)
Mar-11-24 10:04AM	After crushing loss last year, Acelyrin rebounds with psoriatic arthritis victory (FierceBiotech.com) +10.96%
08:02AM	ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis (GlobeNewswire)
08:00AM	ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for Patients (GlobeNewswire)
Feb-15-24 04:05PM	ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications (GlobeNewswire)
Jan-10-24 11:30AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire) -5.08%
Jan-04-24 09:56AM	Final Deadline Approaching for Acelyrin, Inc. Investors: Kessler Topaz Meltzer & Check, LLP Reminds Acelyrin, Inc. (SLRN) Investors of January 16, 2024 Lead Plaintiff Deadline (GlobeNewswire)
Jan-01-24 09:35AM	Acelyrin (SLRN) Faces Investor Fraud Lawsuit for Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Dec-27-23 10:45AM	ACELYRIN SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Acelyrin To Contact Him Directly To Discuss Their Options (GlobeNewswire)
04:30PM	Loading…
Dec-20-23 04:30PM	ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors (GlobeNewswire) -5.94%
Dec-19-23 12:13AM	Robbins LLP Reminds Investors of Lawsuit Against Acelyrin, Inc. and Approaching Lead Plaintiff Deadline (GlobeNewswire)
Dec-18-23 04:14PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire) -7.49%
Dec-12-23 09:25PM	ACELYRIN, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2024 deadline (GlobeNewswire)
Dec-11-23 09:35AM	SLRN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that ACELYRIN, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire) -7.47%
Dec-04-23 03:00PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress - Hagens Berman (GlobeNewswire)
08:00AM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
Nov-30-23 04:30PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire) +5.66%
Nov-28-23 05:55PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; January 16, 2023 deadline (GlobeNewswire) -32.41%
01:44PM	Kaplan Fox & Kilsheimer LLP Investigates Acelyrin, Inc. (Nasdaq: SLRN) (GlobeNewswire)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
Nov-27-23 09:09PM	Acelyrin blames CRO error for shocking phase 3 failure that sent shiver through biotech IPO market (FierceBiotech.com)
04:30PM	ACELYRIN, INC. Provides Update on Izokibep Clinical Development Program (GlobeNewswire)
Nov-20-23 11:01AM	Acelyrin (SLRN) Faces Lawsuit after Allegedly Lying About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
Nov-16-23 06:42PM	Investors Say Acelyrin (SLRN) Lied About Drug Candidate's Progress-Hagens Berman (GlobeNewswire)
04:11PM	Loading…
04:11PM	ACELYRIN, Inc. investors: Please contact the Portnoy Law Firm to recover your losses (GlobeNewswire)
Nov-07-23 05:11PM	Acelyrin Inc (SLRN) Reports Q3 2023 Financial Results: Key Clinical Trials Progressing (GuruFocus.com)
04:05PM	ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Nov-06-23 07:00AM	ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations Officer (GlobeNewswire)
Oct-31-23 04:30PM	ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023 (GlobeNewswire)
Oct-18-23 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Acelyrin, and Clorox and Encourages Investors to Contact the Firm (GlobeNewswire)
Oct-03-23 07:00AM	ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of Development (GlobeNewswire)
Sep-15-23 05:39PM	Why Acelyrin Stock Plummeted 59% This Week (Motley Fool)
Sep-11-23 04:05PM	ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire)
Sep-06-23 07:00AM	ACELYRIN, INC. to Present at the Morgan Stanley 21st Annual Global Healthcare Conference (GlobeNewswire)
Aug-15-23 07:22PM	Billionaire Ken Griffin Pours Millions Into These 2 Strong Buy Stocks Heres Why You Might Want to Ride His Coattails (TipRanks) +7.70%
Aug-14-23 04:05PM	ACELYRIN, INC. Reports Second Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
Aug-07-23 04:30PM	ACELYRIN, INC. to Present Second Quarter 2023 Financial Results and Corporate Update on August 14, 2023 (GlobeNewswire)
Jul-18-23 07:00AM	ACELYRIN, INC. Appoints Ken Lock as Chief Commercial Officer (GlobeNewswire)
Jun-15-23 04:05PM	ACELYRIN, INC. Reports First Quarter 2023 Financial Results and Recent Highlights (GlobeNewswire)
May-09-23 04:10PM	ACELYRIN, INC. Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
May-05-23 07:08PM	Drug Developer Acelyrin Raises $540 Million in IPO (The Wall Street Journal)

ACELYRIN, Inc. operates as a biopharma company. It engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company was founded by Shao-Lee Lin on July 27, 2020 and is headquartered in Agoura Hills, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lin Shao-Lee	Chief Executive Officer	Apr 01 '24	Sale	6.63	9,961	66,024	1,577,374	Apr 03 06:18 PM
Lin Shao-Lee	Chief Executive Officer	Feb 20 '24	Sale	7.60	15,701	119,403	1,587,335	Feb 22 07:04 PM
Lin Shao-Lee	Chief Executive Officer	Jan 02 '24	Sale	7.41	10,691	79,188	1,603,036	Jan 04 06:09 PM
Westlake BioPartners Fund II,	10% Owner	May 09 '23	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:16 PM
SEIDENBERG BETH C	Director	May 09 '23	Buy	18.00	1,250,000	22,500,000	9,790,729	May 11 09:13 PM
SEIDENBERG BETH C	Director	May 09 '23	Buy	18.00	60,000	1,080,000	60,000	May 11 09:13 PM
Gosebruch Henry O	Director	May 09 '23	Buy	18.00	50,000	900,000	50,000	May 11 09:06 PM
Svoronos Dawn	Director	May 09 '23	Buy	18.00	15,000	270,000	15,000	May 11 09:11 PM
Peloso Paul	Chief Medical Officer	May 09 '23	Buy	18.00	6,000	108,000	6,000	May 11 08:54 PM
Dier Mardi	CFO and CBO	May 09 '23	Buy	18.00	5,556	100,008	5,556	May 11 08:51 PM
Kim Mina	Chief Legal & Admin. Officer	May 09 '23	Buy	18.00	5,000	90,000	5,000	May 11 08:58 PM
Becker Daniel J.	Director	May 09 '23	Buy	18.00	3,000	54,000	3,000	May 11 09:02 PM
Dier Mardi	CFO and CBO	May 09 '23	Buy	18.00	1,750	31,500	875	May 11 08:51 PM
Oyston Ronald	Chief People Officer	May 09 '23	Buy	18.00	1,000	18,000	1,000	May 11 09:00 PM
Oyston Ronald	Chief People Officer	May 09 '23	Buy	18.00	26	468	26	May 11 09:00 PM

Open in Screener

RARE

Ultragenyx Pharmaceutical Inc.

May 03 • 04:00PM ET

42.75

Dollar change -0.45
Percentage change -1.04	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

RARE Ultragenyx Pharmaceutical Inc. daily Stock Chart

Held by: VTI VB VXF VBK IBB SCHA IWP VHT IWF IWR

Index	-	P/E	-	EPS (ttm)	-8.03	Insider Own	6.45%	Shs Outstand	82.31M	Perf Week	-3.37%
Market Cap	3.52B	Forward P/E	-	EPS next Y	-5.26	Insider Trans	-1.84%	Shs Float	77.02M	Perf Month	-9.20%
Income	-613.35M	PEG	-	EPS next Q	-1.71	Inst Own	104.14%	Short Float	5.69%	Perf Quarter	-0.63%
Sales	442.59M	P/S	7.95	EPS this Y	20.23%	Inst Trans	-3.13%	Short Ratio	6.11	Perf Half Y	18.62%
Book/sh	1.69	P/B	25.33	EPS next Y	20.09%	ROA	-45.59%	Short Interest	4.38M	Perf Year	-1.34%
Cash/sh	5.08	P/C	8.41	EPS next 5Y	8.90%	ROE	-340.05%	52W Range	31.52 - 54.98	Perf YTD	-10.60%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-15.75%	ROI	-60.31%	52W High	-22.24%	Beta	0.62
Dividend TTM	-	Quick Ratio	2.28	Sales past 5Y	63.06%	Gross Margin	86.59%	52W Low	35.63%	ATR (14)	2.08
Dividend Ex-Date	-	Current Ratio	2.43	EPS Y/Y TTM	21.74%	Oper. Margin	-131.15%	RSI (14)	40.31	Volatility	4.72% 4.98%
Employees	1276	Debt/Eq	6.65	Sales Y/Y TTM	15.29%	Profit Margin	-138.58%	Recom	1.29	Target Price	89.38
Option/Short	Yes / Yes	LT Debt/Eq	6.25	EPS Q/Q	13.10%	Payout	-	Rel Volume	1.59	Prev Close	43.20
Sales Surprise	-6.20%	EPS Surprise	-16.19%	Sales Q/Q	8.30%	Earnings	May 02 AMC	Avg Volume	717.57K	Price	42.75
SMA20	-6.00%	SMA50	-9.86%	SMA200	1.53%	Trades		Volume	1,143,009	Change	-1.04%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-22-24	Initiated	RBC Capital Mkts	Outperform	$77
Dec-08-23	Initiated	Wells Fargo	Overweight	$72
Jun-14-23	Resumed	Credit Suisse	Outperform	$96
Jun-06-23	Upgrade	Evercore ISI	In-line → Outperform	$60 → $80
Apr-26-23	Initiated	Cantor Fitzgerald	Overweight	$114
Jan-18-23	Resumed	Canaccord Genuity	Buy	$90
Dec-30-22	Resumed	H.C. Wainwright	Buy	$82
Nov-03-22	Upgrade	Robert W. Baird	Neutral → Outperform	$50
Oct-13-22	Upgrade	Guggenheim	Neutral → Buy	$50
Aug-01-22	Downgrade	Evercore ISI	Outperform → In-line	$95 → $60
Mar-16-22	Upgrade	Credit Suisse	Neutral → Outperform	$99 → $105
Feb-11-22	Upgrade	JP Morgan	Neutral → Overweight	$132
Sep-30-21	Initiated	H.C. Wainwright	Buy	$106
Aug-19-21	Initiated	UBS	Sell	$73
Jul-15-21	Initiated	Guggenheim	Neutral
Jun-29-21	Upgrade	BofA Securities	Neutral → Buy	$162
Jun-04-21	Resumed	Robert W. Baird	Neutral	$109
May-06-21	Upgrade	Evercore ISI	In-line → Outperform	$144
May-06-21	Upgrade	Citigroup	Neutral → Buy	$160 → $151
Apr-26-21	Resumed	Credit Suisse	Neutral	$99

Show Previous Ratings

May-03-24 03:01PM	Ultragenyx Pharmaceutical Inc (RARE) (Q1 2024) Earnings Call Transcript Highlights: Key ... (GuruFocus.com)
12:22PM	Ultragenyx (RARE) Q1 Loss Wider Than Expected, Revenues Rise Y/Y (Zacks)
May-02-24 08:58PM	RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:00PM	Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:49PM	Ultragenyx Pharmaceutical Inc (RARE) Q1 2024 Earnings: Misses EPS Estimates, Revenue Grows ... (GuruFocus.com)
05:10PM	Loading…
05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:08PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press Finance)
04:00PM	Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-30-24 04:00PM	Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease (GlobeNewswire)
08:00AM	Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Apr-25-24 04:30PM	Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update (GlobeNewswire)
Apr-19-24 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-16-24 11:33AM	Ultragenyx (RARE) Meets Efficacy Goal in Neuro Disease Study (Zacks)
Apr-15-24 07:30AM	Ultragenyx says Angelman therapy is working, but safety questions remain (BioPharma Dive) -8.79%
07:00AM	Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102 (GlobeNewswire)
04:22PM	Loading…
Apr-12-24 04:22PM	Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome (GlobeNewswire) -7.30%
08:00AM	Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting (GlobeNewswire)
Mar-22-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-20-24 08:11AM	10 NASDAQ Stocks with Biggest Upside (Insider Monkey)
Mar-12-24 05:00PM	Insider Sell: CBO & EVP Thomas Kassberg Sells 11,509 Shares of Ultragenyx Pharmaceutical ... (GuruFocus.com)
Mar-11-24 03:00PM	Director Matthew Fust Sells 12,195 Shares of Ultragenyx Pharmaceutical Inc (RARE) (GuruFocus.com)
Mar-08-24 09:38AM	10 Biotech Stocks with Huge Potential (Insider Monkey)
Feb-27-24 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire) +6.79%
Feb-23-24 04:05PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-24 10:43AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.75%
10:35AM	Q4 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
07:53AM	Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat (Zacks)
Feb-15-24 04:15PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-13-24 01:36PM	15 Best Strong Buy Stocks To Invest In (Insider Monkey) -5.91%
04:00PM	Loading…
Feb-08-24 04:00PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2023 Financial Results and Corporate Update (GlobeNewswire)
Feb-06-24 08:00AM	Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Feb-05-24 04:05PM	Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome (GlobeNewswire)
Jan-25-24 04:05PM	Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jan-19-24 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-18-24 02:41PM	Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 (Investor's Business Daily)
Jan-09-24 06:20PM	After Golden Cross, Ultragenyx (RARE)'s Technical Outlook is Bright (Zacks)
Jan-08-24 12:18PM	Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint (Zacks)
07:00AM	Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments (GlobeNewswire)
Jan-07-24 11:00AM	Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones (GlobeNewswire)
Jan-04-24 08:12AM	Ultragenyx (RARE) Posts Update From AS Study of GTX-102 (Zacks)
08:00AM	Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Jan-03-24 08:00AM	Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome (GlobeNewswire)
Jan-02-24 04:05PM	Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-21-23 05:21PM	Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims (The Wall Street Journal)
04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-18-23 09:29AM	Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome (PR Newswire)
08:00AM	Ultragenyx Receives European Commission Decision for Evkeeza (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Dec-15-23 10:18AM	5 Most Promising Biotech Stocks to Buy According to Analysts (Insider Monkey)
Nov-20-23 04:30PM	Ultragenyx to Participate at Investor Conferences in November (GlobeNewswire)
Nov-17-23 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-07-23 05:00PM	Ultragenyx to Participate in the Jefferies London Healthcare Conference (GlobeNewswire)
Nov-04-23 01:12PM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q3 2023 Earnings Call Transcript (Insider Monkey)
12:16PM	12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds (Insider Monkey)
Nov-03-23 11:43AM	Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates (Zacks) +6.09%
Nov-02-23 06:26PM	Ultragenyx Pharmaceutical Inc (RARE) Reports Q3 2023 Earnings: Revenue Grows by 8% Year-Over-Year (GuruFocus.com)
04:36PM	Ultragenyx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Oct-26-23 04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update (GlobeNewswire) +5.12%
Oct-25-23 06:17AM	Insider Sell: CBO & EVP Thomas Kassberg Sells 39,878 Shares of Ultragenyx Pharmaceutical Inc (GuruFocus.com)
Oct-23-23 04:01PM	Ultragenyx Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
04:01PM	Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update (GlobeNewswire)
Oct-20-23 04:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-18-23 09:16PM	Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) -13.85%
Oct-17-23 04:02PM	Ultragenyx Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Oct-16-23 08:00AM	Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing Studies in Osteogenesis Imperfecta (OI), Angelman Syndrome (AS) and Wilson Disease (GlobeNewswire) +10.28%
Oct-14-23 04:30PM	Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-12-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -9.98%
Oct-09-23 08:00AM	Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI) (GlobeNewswire)
Oct-05-23 08:00AM	Ultragenyx to Present Pipeline Update at Analyst Day on Monday, October 16, 2023 (GlobeNewswire)
Sep-25-23 05:13PM	Ultragenyx Launches Evkeeza® (evinacumab for injection) in Canada for the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) (GlobeNewswire)
Sep-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-07-23 12:36PM	Is Ultragenyx Pharmaceutical (RARE) Too Good to Be True? A Comprehensive Analysis of a ... (GuruFocus.com) +6.06%
Aug-31-23 09:00AM	Ultragenyx to Participate at Investor Conferences in September (GlobeNewswire)
Aug-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-12-23 11:05AM	10 Oversold Healthcare Stocks to Buy (Insider Monkey)
Aug-11-23 11:14AM	Henrietta Lacks' estate sues Ultragenyx over Mass.-made gene therapies (American City Business Journals)
Aug-10-23 06:27PM	Henrietta Lacks' family sues Ultragenyx over use of HeLa cell line (Reuters)
Aug-08-23 07:11AM	Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Could Be 41% Below Their Intrinsic Value Estimate (Simply Wall St.)
06:20AM	15 Worst Performing Biotech Stocks in 2023 (Insider Monkey)
Aug-04-23 08:34AM	Q2 2023 Ultragenyx Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents) -8.79%
08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Aug-03-23 04:09PM	Ultragenyx: Q2 Earnings Snapshot (AP Finance)
04:00PM	Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
Jul-31-23 08:00AM	Ultragenyx Announces Initiation of Dosing in Second Cohort of Pivotal Phase 1/2/3 Cyprus2+ Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease (GlobeNewswire)
Jul-27-23 05:00PM	Ultragenyx to Host Conference Call for Second Quarter 2023 Financial Results and Corporate Update (GlobeNewswire)
05:05AM	Can Mass. move beyond R&D to become a biomanufacturing leader? (American City Business Journals)
Jul-18-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-13-23 03:00PM	10 Best Revenue Growth Stocks to Buy (Insider Monkey)
Jul-12-23 08:00AM	Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy (GlobeNewswire)
Jul-07-23 07:46AM	Ultragenyx (RARE) Doses First Patients in Bone Disease Studies (Zacks)
Jul-06-23 08:00AM	Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI) (GlobeNewswire)
Jun-28-23 11:06AM	This Biotech Stock Could Be a RARE Find (TheStreet.com)
Jun-21-23 08:00AM	Ultragenyx Opens New Gene Therapy Manufacturing Facility in Bedford, Continuing its Expansion in Massachusetts (GlobeNewswire)
Jun-20-23 05:00PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-09-23 10:55AM	13 Best Future Stocks for the Long-Term (Insider Monkey)
Jun-07-23 05:00PM	Ultragenyx to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference (GlobeNewswire)
03:21AM	4 big analyst picks: YEXT riding high (Investing.com)
Jun-05-23 04:00PM	Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI) (GlobeNewswire)

Ultragenyx Pharmaceutical, Inc. engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010, and is headquartered in Novato, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Crombez Eric	EVP and Chief Medical Officer	May 02 '24	Sale	43.66	354	15,456	48,431	May 03 03:23 PM
Crombez Eric	EVP and Chief Medical Officer	Apr 18 '24	Sale	44.10	142	6,262	48,785	Apr 19 04:35 PM
Kassberg Thomas Richard	CBO & EVP	Mar 11 '24	Sale	49.93	11,509	574,644	252,823	Mar 12 01:41 PM
Fust Matthew K	Director	Mar 07 '24	Sale	50.88	12,195	620,443	14,860	Mar 11 12:54 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 01 '24	Sale	53.76	4,768	256,328	67,163	Mar 05 08:08 PM
Pinion John Richard	See Remarks	Mar 01 '24	Sale	53.76	4,173	224,340	89,268	Mar 05 08:15 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 01 '24	Sale	53.76	3,756	201,923	67,340	Mar 05 08:22 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 01 '24	Sale	53.76	1,238	66,555	48,927	Mar 05 08:10 PM
Kassberg Thomas Richard	CBO & EVP	Mar 01 '24	Sale	53.76	1,011	54,351	264,332	Mar 05 08:19 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 01 '24	Sale	53.76	341	18,332	41,380	Mar 05 08:13 PM
KAKKIS EMIL D	President & CEO	Feb 07 '24	Sale	45.00	30,000	1,350,000	539,770	Feb 08 03:49 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Jan 02 '24	Option Exercise	21.00	3,000	63,000	27,892	Jan 02 04:06 PM
KAKKIS EMIL D	President & CEO	Dec 29 '23	Sale	47.87	30,000	1,436,100	569,770	Jan 02 04:07 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Option Exercise	6.86	39,878	273,563	286,738	Oct 24 05:22 PM
Kassberg Thomas Richard	CBO & EVP	Oct 23 '23	Sale	32.78	39,878	1,307,201	246,860	Oct 24 05:22 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Option Exercise	6.86	47,853	328,272	647,029	Oct 23 05:14 PM
KAKKIS EMIL D	President & CEO	Oct 19 '23	Sale	33.52	47,853	1,604,033	599,743	Oct 23 05:14 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Option Exercise	21.00	2,000	42,000	25,777	Sep 11 01:52 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 07 '23	Sale	40.80	2,163	88,249	23,614	Sep 11 01:52 PM
Harris Erik	EVP & Chief Commercial Officer	Sep 05 '23	Sale	37.96	6,000	227,760	51,281	Sep 06 05:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 01 '23	Sale	37.15	970	36,032	23,777	Sep 06 05:50 PM
Sanders Corazon (Corsee) D.	Director	Jun 30 '23	Sale	46.76	585	27,355	8,985	Jun 30 02:34 PM
Harris Erik	EVP & Chief Commercial Officer	Jun 19 '23	Sale	48.20	305	14,701	57,281	Jun 21 06:17 PM
Sanders Corazon (Corsee) D.	Director	Jun 08 '23	Sale	51.65	1,485	76,700	9,570	Jun 09 02:31 PM
Pinion John Richard	See Remarks	May 18 '23	Sale	50.00	2,012	100,600	74,744	May 19 01:54 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	May 09 '23	Option Exercise	21.00	3,000	63,000	30,747	May 10 08:09 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

SLRN

Acelyrin Inc

RARE

Ultragenyx Pharmaceutical Inc.

Upgrade your FINVIZ experience